drugset / Trial / NCT01810770

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

NCT01810770

Phase 3 Completed 243 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy (Overall survival \[OS\]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.

Timeline

Start
2013-03-26
Primary completion
2017-09-25
Completion
2017-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Radium-223 dichloride Other / unclassified 0.055 mbq/kg Intravenous

Indications